First-in-class antibody-drug conjugate for NaPi2b-expressing tumors divulged
Oct. 23, 2023
NaPi2b is a sodium-dependent phosphate transporter that is mainly responsible for phosphate homeostasis in humans. Overexpression of NaPi2b has been associated with several types of cancers such as lung, ovarian, thyroid or breast carcinomas and thus is considered a therapeutic target to exploit in these conditions.